文献速递哮喘

重度哮喘患者血浆蛋白升高且与2型炎症无关,不受口服激素影响

Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
PubMed 文献 · Eur Respir J · 2022-02-17

该研究应用靶向177种蛋白的抗体芯片,检测U-BIOPRED队列525例哮喘患者和健康对照及BIOAIR验证队列142例受试者的血浆蛋白,发现重度哮喘患者多种蛋白显著升高,且差异在校正口服激素使用后仍存在,聚类分析提示与2型炎症无关。

要点

  • 重度哮喘患者血浆中110种蛋白显著升高,多与炎症、脂质代谢、信号转导和细胞外基质相关。
  • 10种蛋白在U-BIOPRED和BIOAIR两个队列中均显示重度哮喘高于轻中度哮喘。
  • 口服激素治疗降低多数蛋白,但重度与轻中度哮喘间的差异在校正后仍持续存在。

核心结论

  • 血浆蛋白组芯片揭示了与2型炎症无关的潜在生物标志物。
  • 验证了多种与重度哮喘病理生理相关的蛋白。

研究设计与样本

  • 研究应用靶向177种蛋白的抗体芯片,检测U-BIOPRED队列525例哮喘患者和健康对照及BIOAIR队列142例哮喘和COPD受试者的血浆。
  • BIOAIR中通过2周安慰剂对照口服激素试验确定口服激素效应,并在U-BIOPRED中与客观口服激素指标关联确认。

主要发现

  • U-BIOPRED中重度哮喘与轻中度哮喘及健康对照相比有110种蛋白显著不同,多数升高。
  • U-BIOPRED和BIOAIR中均显示重度哮喘高于轻中度哮喘的10种蛋白为:alpha-1-antichymotrypsin、apolipoprotein-E、complement component 9、complement factor I、macrophage inflammatory protein-3、interleukin-6、sphingomyelin phosphodiesterase 3、TNF receptor superfamily member 11a、transforming growth factor-β和glutathione S-transferase。
  • 口服激素治疗降低多数蛋白,但校正口服激素使用后重度与轻中度哮喘间差异仍存在。
  • U-BIOPRED蛋白数据的共识聚类得到6个聚类,与哮喘控制、生活质量、血中性粒细胞、高敏C反应蛋白和体重指数相关,但与2型炎症生物标志物无关。
  • 肥大细胞特异性酶carboxypeptidase A3是聚类区分的主要贡献者之一。

临床怎么用

  • 血浆蛋白组面板可用于识别重度哮喘中非2型炎症的生物标志物。
  • 解读重度哮喘蛋白标志物时需考虑口服激素使用的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Asthma phenotyping requires novel biomarker discovery. OBJECTIVES: To identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of severe (SA) and mild-to-moderate (MMA) asthmatics, COPD subjects and healthy controls (HCs). METHODS: An antibody-based array targeting 177 proteins predominantly involved in pathways relevant to inflammation, lipid metabolism, signal transduction and extracellular matrix was applied to plasma from 525 asthmatics and HCs in the U-BIOPRED cohort, and 142 subjects with asthma and COPD from the validation cohort BIOAIR. Effects of oral corticosteroids (OCS) were determined by a 2-week, placebo-controlled OCS trial in BIOAIR, and confirmed by relation to objective OCS measures in U-BIOPRED. RESULTS: In U-BIOPRED, 110 proteins were significantly different, mostly elevated, in SA compared to MMA and HCs. 10 proteins were elevated in SA versus MMA in both U-BIOPRED and BIOAIR (alpha-1-antichymotrypsin, apolipoprotein-E, complement component 9, complement factor I, macrophage inflammatory protein-3, interleukin-6, sphingomyelin phosphodiesterase 3, TNF receptor superfamily member 11a, transforming growth factor-β and glutathione S-transferase). OCS treatment decreased most proteins, yet differences between SA and MMA remained following correction for OCS use. Consensus clustering of U-BIOPRED protein data yielded six clusters associated with asthma control, quality of life, blood neutrophils, high-sensitivity C-reactive protein and body mass index, but not Type-2 inflammatory biomarkers. The mast cell specific enzyme carboxypeptidase A3 was one major contributor to cluster differentiation. CONCLUSIONS: The plasma proteomic panel revealed previously unexplored yet potentially useful Type-2-independent biomarkers and validated several proteins with established involvement in the pathophysiology of SA.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Sparreman Mikus M, Kolmert J, Andersson LI, et al. Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. Eur Respir J. 2022. PMID: 34737220. doi:10.1183/13993003.00142-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。